Nonetheless, CSPG4 represents a promising target for adoptive T cell therapies, as it is not only overexpressed in melanoma but also in a broad range of other malignancies such as triple-negative breast cancers, various types of gliomas, head and neck squamous-cell carcinomas, soft-tissue sarcomas, tumor-associated vasculature and also leukemia (11–13). This evidence concerns the gene CSPG4 and soft tissue sarcoma.